CD80 and cancer: In cancer, CTLA4 is harnessed by cancer cells to hinder the antitumor immune response through manipulation of the expression of CTLA4 ligands (CD80 and CD86) on APCs within the tumor microenvironment, enabling CTLA4 on regulatory T cells (Tregs) to suppress cytotoxic T cell activity.